Recent developments in vaccines and biological therapies against Japanese encephalitis virus

References

• World Health Organization. Japanese encephalitis vaccines: WHO position paper – February 2015. Wkly Epidemiol Rec. 2015;90:69–87.
   PubMedGoogle Scholar
• Campbell G, Hills S, Fischer M, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011;89:766–74,774A–774E.
   PubMed Web of Science ®Google Scholar
• Turtle L, Driver C. Risk assessment for Japanese encephalitis vaccination. Hum Vaccin Immunother. 2018 Jan 2;14(1):213–217.
   PubMed Web of Science ®Google Scholar
• Heffelfinger JD, Li X, Batmunkh N, et al. Japanese Encephalitis Surveillance and Immunization - Asia and Western Pacific Regions, 2016. MMWR Morb Mortal Wkly Rep. 2017;66:579–583.
   PubMed Web of Science ®Google Scholar
• Hanna JN, Ritchie SA, Phillips DA, et al. An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. Med J Aust. 1996;165:256–260.
   PubMed Web of Science ®Google Scholar
• Hanna JN, Ritchie SA, Phillips DA, et al. Japanese encephalitis in north Queensland, Australia, 1998. Med J Aust. 1999;170:533–536.
   PubMed Web of Science ®Google Scholar
• Ravanini P, Huhtamo E, Ilaria V, et al. Japanese encephalitis virus RNA detected in Culex pipiens mosquitoes in Italy. Euro Surveill. 2012;17:pii: 20221.
   PubMedGoogle Scholar
• Simon-Loriere E, Faye O, Prot M, et al. Autochthonous Japanese encephalitis with yellow fever coinfection in Africa. N Engl J Med. 2017;376:1483–1485.
   PubMed Web of Science ®Google Scholar
• Buescher EL, Scherer WF, Rosenberg MZ, et al. Ecologic studies of Japanese encephalitis virus in Japan. II. Mosquito infection. Am J Trop Med Hyg. 1959;8:651–664.
   PubMed Web of Science ®Google Scholar
• Buescher EL, Scherer WF, McClure HE, et al. Ecologic studies of Japanese encephalitis virus in Japan. IV. Avian infection. Am J Trop Med Hyg. 1959;8:678–688.
   PubMed Web of Science ®Google Scholar
• Buescher EL, Scherer WF. Ecologic studies of Japanese encephalitis virus in Japan. IX. Epidemiologic correlations and conclusions. Am J Trop Med Hyg. 1959;8:719–722.
   PubMed Web of Science ®Google Scholar
• Halstead SB, Jacobson J. Japanese encephalitis. Adv Virus Res. 2003;61:103–138.
   PubMedGoogle Scholar
• Xu Y, Zhaori G, Vene S, et al. Viral etiology of acute childhood encephalitis in Beijing diagnosed by analysis of single samples. Pediatr Infect Dis J. 1996;15:1018–1024.
   PubMed Web of Science ®Google Scholar
• Kumari R, Kumar K, Rawat A, et al. First indigenous transmission of Japanese encephalitis in urban areas of National Capital Territory of Delhi, India. Trop Med Int Health. 2013;18:743–749.
   PubMed Web of Science ®Google Scholar
• Grossman RA, Edelman R, Willhight M, et al. Study of Japanese encephalitis virus in Chiangmai Valley, Thailand. 3. Human seroepidemiology and inapparent infections. Am J Epidemiol. 1973;98:133–149.
   PubMed Web of Science ®Google Scholar
• Watt G, Jongsakul K. Acute undifferentiated fever caused by infection with Japanese encephalitis virus. Am J Trop Med Hyg. 2003;68:704–706.
   PubMed Web of Science ®Google Scholar
• Griffiths MJ, Turtle L, Solomon T. Japanese encephalitis virus infection. Handb Clin Neurol. 2014;123:561–576.
   PubMedGoogle Scholar
• Solomon T, Dung NM, Kneen R, et al. Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis. Brain. 2002;125:1084–1093.
   PubMed Web of Science ®Google Scholar
• Hills SL, Griggs AC, Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973-2008. Am J Trop Med Hyg. 2010;82:930–936.
   PubMed Web of Science ®Google Scholar
• Solomon T, Dung NM, Kneen R, et al. Japanese encephalitis. J Neurol Neurosurg Psychiat. 2000;68:405–415.
   PubMed Web of Science ®Google Scholar
• Kumar R, Tripathi P, Singh S, et al. Clinical features in children hospitalized during the 2005 epidemic of Japanese encephalitis in Uttar Pradesh, India. Clin Infect Dis. 2006;43:123–131.
   PubMed Web of Science ®Google Scholar
• Ooi MH, Lewthwaite P, Lai BF, et al. The epidemiology, clinical features, and long-term prognosis of Japanese encephalitis in Central Sarawak, Malaysia, 1997-2005. Clin Infect Dis. 2008;47:458–468.
   PubMed Web of Science ®Google Scholar
• Tsarev SA, Sanders ML, Vaughn DW, et al. Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus. Vaccine. 2000;18(Suppl 2):36–43.
   PubMed Web of Science ®Google Scholar
• Uchil PD, Satchidanandam V. Phylogenetic analysis of Japanese encephalitis virus: envelope gene based analysis reveals a fifth genotype, geographic clustering, and multiple introductions of the virus into the Indian subcontinent. Am J Trop Med Hyg. 2001;65:242–251.
   PubMed Web of Science ®Google Scholar
• Morita K. Molecular epidemiology of Japanese encephalitis in East Asia. Vaccine. 2009;27:7131–7132.
   PubMed Web of Science ®Google Scholar
• Markoff L. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine. 2000;18(Suppl 2):26–32.
   PubMed Web of Science ®Google Scholar
• Erra EO, Askling HH, Yoksan S, et al. Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes. Clin Infect Dis. 2013;56:267–270.
   PubMed Web of Science ®Google Scholar
• Bonaparte M, Dweik B, Feroldi E, et al. Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India. BMC Infect Dis. 2014;14:156.
   PubMed Web of Science ®Google Scholar
• Singh A, Mitra M, Sampath G, et al. A Japanese encephalitis vaccine from India induces durable and cross-reactive immunity against temporally and spatially wide-ranging global field strains. J Infect Dis. 2015;212:715–725.
   PubMed Web of Science ®Google Scholar
• Pan XL, Liu H, Wang HY, et al. Emergence of genotype I of Japanese encephalitis virus as the dominant genotype in Asia. J Virol. 2011;85:9847–9853.
   PubMed Web of Science ®Google Scholar
• Lannes N, Summerfield A, Filgueira L. Regulation of inflammation in Japanese encephalitis. J Neuroinflammation. 2017;14:158.
   PubMed Web of Science ®Google Scholar
• Myint KS, Kipar A, Jarman RG, et al. Neuropathogenesis of Japanese encephalitis in a primate model. PLoS Negl Trop Dis. 2014;8:e2980.
   PubMed Web of Science ®Google Scholar
• Burke DS, Lorsomrudee W, Leake CJ, et al. Fatal outcome in Japanese encephalitis. Am J Trop Med Hyg. 1985;34:1203–1210.
   PubMed Web of Science ®Google Scholar
• Solomon T. Flavivirus encephalitis. N Engl J Med. 2004;351:370–378.
   PubMed Web of Science ®Google Scholar
• Van Gessel Y, Klade CS, Putnak R, et al. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO) induced neutralizing antibody titres. Vaccine. 2011;29:5925–5931.
   PubMed Web of Science ®Google Scholar
• Turtle L, Bali T, Buxton G, et al. Human T cell responses to Japanese encephalitis virus in health and disease. J Exp Med. 2016;213:1331–1352.
   PubMed Web of Science ®Google Scholar
• Jain N, Oswal N, Chawla AS, et al. CD8 T cells protect adult naive mice from JEV-induced morbidity via lytic function. PLoS Negl Trop Dis. 2017;11:e0005329.
   PubMed Web of Science ®Google Scholar
• Larena M, Regner M, Lee E, et al. Pivotal role of antibody and subsidiary contribution of CD8+ T cells to recovery from infection in a murine model of Japanese encephalitis. J Virol. 2011;85:5446–5455.
   PubMed Web of Science ®Google Scholar
• Yang Y, Liang N, Tan Y, et al. Epidemiological trends and characteristics of Japanese encephalitis changed based on the vaccination program between 1960 and 2013 in Guangxi Zhuang Autonomous Region, southern China. Int J Infect Dis. 2016;45:135–138.
   PubMed Web of Science ®Google Scholar
• Sunwoo JS, Jung KH, Lee ST, et al. Reemergence of Japanese Encephalitis in South Korea, 2010-2015. Emerg Infect Dis. 2016;22:1841–1843.
   PubMed Web of Science ®Google Scholar
• Amicizia D, Zangrillo F, Lai PL, et al. Overview of Japanese encephalitis disease and its prevention. Focus on IC51 vaccine (IXIARO®). J Prev Med Hyg. 2018;59:E99–E107.
   PubMedGoogle Scholar
• Gao X, Li X, Li M, et al. Vaccine strategies for the control and prevention of Japanese encephalitis in Mainland China, 1951-2011. PLoS Negl Trop Dis. 2014;8:e3015.
   PubMed Web of Science ®Google Scholar
• Halstead SB, Thomas SJ. Japanese encephalitis: new options for active immunization. Clin Infect Dis. 2010;50:1155–1164.
   PubMed Web of Science ®Google Scholar
• Hegde NR, Gore MM. Japanese encephalitis vaccines: immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease. Hum Vaccin Immunother. 2017;13:1–18.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Japanese encephalitis surveillance and immunization–Asia and the Western Pacific, 2012. MMWR Morb Mortal Wkly Rep. 2013;62:658–662.
   PubMed Web of Science ®Google Scholar
• Hoke CH, Nisalak A, Sangawhipa N, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med. 1988;319:608–614.
   PubMed Web of Science ®Google Scholar
• Poland JD, Cropp CB, Craven RB, et al. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J Infect Dis. 1990;161:878–882.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Yamanaka A, Konishi E. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine. 2014;32:1326–1337.
   PubMed Web of Science ®Google Scholar
• Plesner AM. Allergic reactions to Japanese encephalitis vaccine. Immunol Allergy Clin North Am. 2003;23:665–697.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Pool V, Tsai TF, et al. Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group. Vaccine. 2000;18:2963–2969.
   PubMed Web of Science ®Google Scholar
• Ferguson M, Kurane I, Wimalaratne O, et al. WHO informal consultation group. WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1–2 June 2006. Vaccine. 2007;25:5233–5243.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Advisory Committee on Vaccine Safety, 9–10 June 2005. Weekly Epidemiol Rec. 2005;80:242–247.
   PubMedGoogle Scholar
• Yu Y. Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine. 2010;28:3635–3641.
   PubMed Web of Science ®Google Scholar
• Gromowski GD, Firestone CY, Bustos-Arriaga J, et al. Genetic and phenotypic properties of Vero cell-adapted Japanese encephalitis virus SA14-14-2 vaccine strain variants and a recombinant clone, which demonstrates attenuation and immunogenicity in mice. Am J Trop Med Hyg. 2015;92:98–107.
   PubMed Web of Science ®Google Scholar
• Yun SI, Song BH, Kim JK, et al. A molecularly cloned, live-attenuated Japanese encephalitis vaccine SA14-14-2 virus: a conserved single amino acid in the IJ hairpin on the viral E glycoprotein determines neurovirulence in mice. PLoS Pathog. 2014;10:e1004290.
   PubMed Web of Science ®Google Scholar
• Fan JM, Luo J, Chen L, et al. Genetic analysis of strains of Japanese encephalitis virus isolated from swine in central China. Virus Genes. 2010;40:357–361.
   PubMed Web of Science ®Google Scholar
• Yang D, Li XF, Ye Q, et al. Characterization of live-attenuated Japanese encephalitis vaccine virus SA14-14-2. Vaccine. 2014;32:2675–2681.
   PubMed Web of Science ®Google Scholar
• Liu ZL, Hennessy S, Strom BL, et al. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects. J Infect Dis. 1997;176:1366–1369.
   PubMed Web of Science ®Google Scholar
• Ginsburg AS, Meghani A, Halstead SB, et al. Use of the live attenuated Japanese Encephalitis vaccine SA 14-14-2 in children: A review of safety and tolerability studies. Hum Vaccin Immunother. 2017;13:2222–2231.
   PubMed Web of Science ®Google Scholar
• Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13–15 October 1998. Vaccine. 2000;18(Suppl. 2):1–25.
   PubMedGoogle Scholar
• Sohn YM, Park MS, Rho HO, et al. Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants. Vaccine. 1999;17:2259–2264.
   PubMed Web of Science ®Google Scholar
• Bista MB, Banerjee MK, Shin SH, et al. Efficacy of single-dose SA14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet. 2001;358:791–795.
   PubMed Web of Science ®Google Scholar
• Ohrr H, Tandan JB, Sohn YM, et al. Effect of single dose of SA14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet. 2005;366:1375–1378.
   PubMed Web of Science ®Google Scholar
• Wijesinghe PR, Abeysinghe MRN, Yoksan S, et al. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine. Vaccine. 2016;34:5923–5928.
   PubMed Web of Science ®Google Scholar
• Vashishtha VM, Kalra A, Bose A, et al. Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years, India, 2013 and updates on immunization. Indian Pediatr. 2013;50:1095–1108.
   PubMed Web of Science ®Google Scholar
• Erra EO, Kantele A. The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis. Expert Rev Vaccines. 2015;14:1167–1179.
   PubMed Web of Science ®Google Scholar
• Tauber E, Kollaritsch H, Von Sonnenburg F, et al. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis. 2008;198:493–499.
   PubMed Web of Science ®Google Scholar
• Schuller E, Klingler A, Dubischar-Kastner K, et al. Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO®. Vaccine. 2011;29:8669–8676.
   PubMed Web of Science ®Google Scholar
• Rabe IB, Miller ER, Fischer M, et al. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012. Vaccine. 2015;33:708–712.
   PubMed Web of Science ®Google Scholar
• Lyons A, Kanesa-Thasan N, Kuschner RA, et al. A phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine. 2007;25:3445–3453.
   PubMed Web of Science ®Google Scholar
• Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet. 2007;370:1847–1853.
   PubMed Web of Science ®Google Scholar
• Kaltenbock A, Dubischar-Kastner K, Schuller E, et al. Immunogenicity and safety of IXIARO® (IC51) in a Phase II study inhealthy Indian children between 1 and 3 years of age. Vaccine. 2010;28:834–839.
   PubMed Web of Science ®Google Scholar
• Dubischar-Kastner K, Eder S, Buerger V, et al. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51. Vaccine. 2010;28:5197–5202.
   PubMed Web of Science ®Google Scholar
• Paulke-Korinek M, Kollaritsch H, Kundi M, et al. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis. Vaccine. 2015;33:3600–3604.
   PubMed Web of Science ®Google Scholar
• Cramer JP, Dubischar K, Eder S, et al. Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: open-label, uncontrolled, multi-center, phase 4 study. Vaccine. 2016;34:4579–4585.
   PubMed Web of Science ®Google Scholar
• Takeshita N, Lim CK, Mizuno Y, et al. Immunogenicity of single-dose Vero cell-derived Japanese encephalitis vaccine in Japanese adults. J Infect Chemother. 2014;20:238–242.
   PubMed Web of Science ®Google Scholar
• Okada K, Iwasa T, Namazue J, et al. Safety and immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated) (JEBIK®V) in children. Vaccine. 2012;30:5967–5972.
   PubMed Web of Science ®Google Scholar
• Kikukawa A, Gomi Y, Akechi M, et al. Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated). Vaccine. 2012;30:2329–2335.
   PubMed Web of Science ®Google Scholar
• Yun KW, Lee HJ, Kang JH, et al. Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial. BMC Infect Dis. 2015;15:7.
   PubMed Web of Science ®Google Scholar
• Chanthavanich P, Limkittikul K, Sirivichayakul C, et al. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children. Hum Vaccin Immunother. 2018;1–6. DOI:10.1080/21645515.2017.1414763
   PubMed Web of Science ®Google Scholar
• Chambers TJ, Nestorowicz A, Mason PW, et al. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol. 1999;73:3095–3101.
   PubMed Web of Science ®Google Scholar
• Guy B, Guirakhoo F, Barban V, et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue. West Nile and Japanese encephalitis viruses. Vaccine. 2010;28:632–649.
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Zhang ZX, Chambers TJ, et al. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology. 1999;257:363–372.
   PubMed Web of Science ®Google Scholar
• Monath TP, Soike K, Levenbook I, et al. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine. 1999;17:1869–1882.
   PubMed Web of Science ®Google Scholar
• Monath TP, Levenbook I, Soike K, et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol. 2000;74:1742–1751.
   PubMed Web of Science ®Google Scholar
• Arroyo J, Guirakhoo F, Fenner S, et al. Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol. 2001;75:934–942.
   PubMed Web of Science ®Google Scholar
• Monath TP, Arroyo J, Levenbook I, et al. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J Virol. 2002;76:1932–1943.
   PubMed Web of Science ®Google Scholar
• Monath TP, Guirakhoo F, Nichols R, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003;188:1213–1230.
   PubMed Web of Science ®Google Scholar
• Bhatt TR, Crabtree MB, Guirakhoo F, et al. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14-14-2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am J Trop Med Hyg. 2000;62:480–484.
   PubMed Web of Science ®Google Scholar
• Feroldi E, Pancharoen C, Kosalaraksa P, et al. Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial. Hum Vaccin Immunother. 2012;8:929–937.
   PubMed Web of Science ®Google Scholar
• Feroldi E, Capeding MR, Boaz M, et al. Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children. Hum Vaccin Immunother. 2013;9:889–897.
   PubMed Web of Science ®Google Scholar
• Capeding MR, Alberto ER, Bouckenooghe A, et al. Five-year antibody persistence following a Japanese encephalitis chimeric virus vaccine (JE-CV) booster in JE-CV–primed children in the Philippines. J Infect Dis. 2018;217:567–571.
   PubMed Web of Science ®Google Scholar
• Kosalaraksa P, Watanaveeradej V, Pancharoen C, et al. Long-term immunogenicity of a single dose of Japanese encephalitis chimeric virus vaccine in toddlers and booster response 5 years after primary immunization. Pediatr Infect Dis J. 2017;36:e108–13.
   PubMed Web of Science ®Google Scholar
• Nasveld PE, Ebringer A, Elmes N, et al. Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults. Hum Vaccin. 2010;6:1038–1046.
   PubMed Web of Science ®Google Scholar
• Chokephaibulkit K, Houillon G, Feroldi E, et al. Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children. Expert Rev Vaccines. 2016;15:153–166.
   PubMed Web of Science ®Google Scholar
• Chokephaibulkit K, Sirivichayakul C, Thisyakorn U, et al. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial. Pediatr Infect Dis J. 2010;29:1111–1117.
   PubMed Web of Science ®Google Scholar
• Feroldi E, Pancharoen C, Kosalaraksa P, et al. Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety. Pediatr Infect Dis J. 2014;33:643–649.
   PubMed Web of Science ®Google Scholar
• Huang LM, Lin TY, Chiu CH, et al. Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: randomized study in toddlers in Taiwan. Vaccine. 2014;32:5363–5369.
   PubMed Web of Science ®Google Scholar
• Torresi J, McCarthy K, Feroldi E, et al. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled phase 3 trials. Vaccine. 2010;28:7993–8000.
   PubMed Web of Science ®Google Scholar
• Kim DS, Houillon G, Jang GC, et al. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric vaccine (JECV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea. Hum Vaccin Immunother. 2014;10:2656–2663.
   PubMed Web of Science ®Google Scholar
• Ferguson M, Johnes S, Li L, et al. Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines – report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies. Biologicals. 2008;36:111–116.
   PubMed Web of Science ®Google Scholar
• Chokephaibulkit K, Sirivichayakul C, Thisyakorn U, et al. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: immune responses in children. Vaccine. 2016;34:5664–5669.
   PubMed Web of Science ®Google Scholar
• Feroldi E, Boaz M, Yoksan S, et al. Persistence of wild-type Japanese encephalitis virus strains cross-neutralization 5 years after JE-CV immunization. J Infect Dis. 2017;215:221–227.
   PubMed Web of Science ®Google Scholar
• Chotpitayasunondh T, Pruekprasert P, Puthanakit T, et al. Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand. Vaccine. 2017;35:299–304.
   PubMed Web of Science ®Google Scholar
• Rey FA, Stiasny K, Vaney MC, et al. The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. EMBO Rep. 2017;pii: e45302.
   PubMed Web of Science ®Google Scholar
• Chen HW, Pan CH, Liau MY, et al. Screening of protective antigens of Japanese encephalitis virus by DNA immunization: a comparative study with conventional viral vaccines. J Virol. 1999;73:10137–10145.
   PubMed Web of Science ®Google Scholar
• Konishi E, Fujii A, Mason PW. Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles. J Virol. 2001;75:2204—12.
   PubMed Web of Science ®Google Scholar
• Konishi E, Pincus S, Paoletti E, et al. Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology. 1992;188:714—20.
   PubMed Web of Science ®Google Scholar
• Qiao M, Ashok M, Bernard KA, et al. Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells. J Infect Dis. 2004;190:2104—8.
   PubMed Web of Science ®Google Scholar
• Cj W, Tl L, Hw H, et al. Development of an effective Japanese encephalitis virus-specific DNA vaccine. Microbes Infect. 2006;8:2578–2586.
   PubMed Web of Science ®Google Scholar
• Xu XG, Wang ZS, Zhang Q, et al. Baculovirus surface display of E envelope glycoprotein of Japanese encephalitis virus and its immunogenicity of the displayed proteins in mouse and swine models. Vaccine. 2011;29:636–643.
   PubMed Web of Science ®Google Scholar
• Higuchi A, Toriniwa H, Komiya T, et al. Recombinant measles AIK-C vaccine strain expressing the prM-E antigen of Japanese encephalitis virus. PLoS One. 2016;11:e0150213.
   PubMed Web of Science ®Google Scholar
• Liu H, Wu R, Liu K, et al. Enhanced immune responses against Japanese encephalitis virus using recombinant adenoviruses coexpressing Japanese encephalitis virus envelope and porcine interleukin-6 proteins in mice. Virus Res. 2016;222:34–40.
   PubMed Web of Science ®Google Scholar
• Kofler RM, Aberle JH, Aberle SW, et al. Mimicking live flavivirus immunization with a noninfectious RNA vaccine. Proc Natl Acad Sci USA. 2004;101:1951—6.
   PubMed Web of Science ®Google Scholar
• Mason PW, Shustov AV, Frolov I. Production and characterization of vaccines based on flaviviruses defective in replication. Virology. 2006;351:432—43.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Widman DG, Bourne N, et al. Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis. Vaccine. 2008;26:2772–2781.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Wang G, Widman DG, et al. Enhancing the utility of a prM/E-expressing chimeric vaccine for Japanese encephalitis by addition of the JEV NS1 gene. Vaccine. 2011;29:7444–7455.
   PubMed Web of Science ®Google Scholar
• Nickols B, Tretyakova I, Tibbens A, et al. Plasmid DNA launches live-attenuated Japanese encephalitis virus and elicits virus-neutralizing antibodies in BALB/c mice. Virology. 2017;512:66–73.
   PubMed Web of Science ®Google Scholar
• Gromowski GD, Firestone CY, Hanson CT, et al. Japanese encephalitis virus vaccine candidates generated by chimerization with dengue virus type 4. Vaccine. 2014;32:3010–3018.
   PubMed Web of Science ®Google Scholar
• Lobigs M, Pavy M, Hall RA, et al. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J Gen Virol. 2010;91:1407–1417.
   PubMed Web of Science ®Google Scholar
• Larena M, Prow NA, Hall RA, et al. JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibody. J Virol. 2013;87:4395–4402.
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Larena M, Siddharthan V, et al. An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody. J Virol. 2013;87:10324–10333.
   PubMed Web of Science ®Google Scholar
• Li Y, Xu M, Chen L, et al. Evaluation of murine bone marrow-derived dendritic cells loaded with inactivated virus as a vaccine against Japanese encephalitis virus. Vaccine. 2009;27:6004–6010.
   PubMed Web of Science ®Google Scholar
• Barnes D, Kunitomi M, Vignuzzi M, et al. Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host Microbe. 2008 Sep 11;4(3):239–248.
   PubMed Web of Science ®Google Scholar
• Yen LC, Lin YL, Sung HH, et al. Neurovirulent flavivirus can be attenuated in mice by incorporation of neuron-specific microRNA recognition elements into viral genome. Vaccine. 2013;31:5915–5922.
   PubMed Web of Science ®Google Scholar
• Teterina NL, Liu G, Maximova OA, et al. Silencing of neurotropic flavivirus replication in the central nervous system by combining multiple microRNA target insertions in two distinct viral genome regions. Virology. 2014;456-457:247–258.
   PubMed Web of Science ®Google Scholar
• Li SH, Dong H, Li XF, et al. Rational design of a flavivirus vaccine by abolishing viral RNA 2ʹ-O methylation. J Virol. 2013;87:5812–5819.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Konishi E. Potential chemotherapeutic targets for Japanese encephalitis: current status of antiviral drug development and future challenges. Expert Opin Ther Targets. 2015;19:1379–1395.
   PubMed Web of Science ®Google Scholar
• Zu X, Liu Y, Wang S, et al. Peptide inhibitor of Japanese encephalitis virus infection targeting envelope protein domain III. Antiviral Res. 2014;104:7–14.
   PubMed Web of Science ®Google Scholar
• Chen L, Liu Y, Wang S, et al. Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses. Antiviral Res. 2017;141:140–149.
   PubMed Web of Science ®Google Scholar
• Li C, Ge LL, Yu YL, et al. A tripeptide (NSK) inhibits Japanese encephalitis virus infection in vitro and in vivo. Arch Virol. 2014;159:1045–1055.
   PubMed Web of Science ®Google Scholar
• Li C, Zhang LY, Sun MX, et al. Inhibition of Japanese encephalitis virus entry into the cells by the envelope glycoprotein domain III (EDIII) and the loop3 peptide derived from EDIII. Antiviral Res. 2012;94:179–183.
   PubMed Web of Science ®Google Scholar
• Qiu X, Lei Y, Yang P, et al. Structural basis for neutralization of Japanese encephalitis virus by two potent therapeutic antibodies. Nat Microbiol. 2018;3:287–294.
   PubMed Web of Science ®Google Scholar
• Rayamajhi A, Nightingale S, Bhatta NK, et al. A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PLoS One. 2015;10:e0122608.
   PubMed Web of Science ®Google Scholar
• Caramello P, Canta F, Balbiano R, et al. Role of intravenous immunoglobulin administration in Japanese encephalitis. Clin Infect Dis. 2006;43:1620–1621.
   PubMed Web of Science ®Google Scholar
• Boldescu V, Behnam MAM, Vasilakis N, et al. Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond. Nat Rev Drug Discov. 2017;16:565–586.
   PubMed Web of Science ®Google Scholar
• Bollati M, Alvarez K, Assenberg R, et al. Structure and functionality in flavivirus NS-proteins: perspectives for drug design. Antiviral Res. 2010;87:125–148.
   PubMed Web of Science ®Google Scholar
• Luo D, Vasudevan SG, Lescar J. The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development. Antiviral Res. 2015;118:148–158.
   PubMed Web of Science ®Google Scholar
• Mastrangelo E, Pezzullo M, De Burghgraeve T, et al. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother. 2012;67:1884–1894.
   PubMed Web of Science ®Google Scholar
• Fang J, Li H, Kong D, et al. Structure-based discovery of two antiviral inhibitors targeting the NS3 helicase of Japanese encephalitis virus. Sci Rep. 2016;6:34550.
   PubMed Web of Science ®Google Scholar
• Li Z, Brecher M, Deng YQ, et al. Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. Cell Res. 2017;27:1046–1064.
   PubMed Web of Science ®Google Scholar
• Li Z, Sakamuru S, Huang R, et al. Erythrosin B is a potent and broad-spectrum orthosteric inhibitor of the flavivirus NS2B-NS3 protease. Antiviral Res. 2018;150:217–225.
   PubMed Web of Science ®Google Scholar
• Brecher M, Chen H, Li Z, et al. Identification and characterization of novel broad-spectrum inhibitors of the flavivirus methyltransferase. ACS Infect Dis. 2015;1:340–349.
   PubMed Web of Science ®Google Scholar
• Han SR, Lee SW. Inhibition of Japanese encephalitis virus (JEV) replication by specific RNA aptamer against JEV methyltransferase. Biochem Biophys Res Commun. 2017;483:687–693.
   PubMed Web of Science ®Google Scholar
• Shen T, Liu K, Miao D, et al. Effective inhibition of Japanese encephalitis virus replication by shRNAs targeting various viral genes in vitro and in vivo. Virology. 2014;454-455:48–59.
   PubMed Web of Science ®Google Scholar
• Anantpadma M, Vrati S. siRNA-mediated suppression of Japanese encephalitis virus replication in cultured cells and mice. J Antimicrob Chemother. 2012;67:444–451.
   PubMed Web of Science ®Google Scholar
• Shen T, Liu K, Miao D, et al. Lentivirus-mediated RNA interference against Japanese encephalitis virus infection in vitro and in vivo. Antiviral Res. 2014;108:56–64.
   PubMed Web of Science ®Google Scholar
• Wu Z, Xue Y, Wang B, et al. Broad-spectrum antiviral activity of RNA interference against four genotypes of Japanese encephalitis virus based on single microRNA polycistrons. PLoS One. 2011;6:e26304.
   PubMed Web of Science ®Google Scholar
• Anantpadma M, Stein DA, Vrati S. Inhibition of Japanese encephalitis virus replication in cultured cells and mice by a peptide-conjugated morpholino oligomer. J Antimicrob Chemother. 2010;65:953–961.
   PubMed Web of Science ®Google Scholar
• Nazmi A, Dutta K, Basu A. Antiviral and neuroprotective role of octaguanidinium dendrimer-conjugated morpholino oligomers in Japanese encephalitis. PLoS Negl Trop Dis. 2010;4:e892.
   PubMed Web of Science ®Google Scholar
• Yoo JS, Kim CM, Kim JH, et al. Inhibition of Japanese encephalitis virus replication by peptide nucleic acids targeting cis-acting elements on the plus- and minus-strands of viral RNA. Antiviral Res. 2009;82:122–133.
   PubMed Web of Science ®Google Scholar
• Solomon T, Dung NM, Wills B, et al. Interferon alfa-2a in Japanese encephalitis: a randomized double-blind placebo-controlled trial. Lancet. 2003;361:821–826.
   PubMed Web of Science ®Google Scholar
• Kumar R, Tripathi P, Baranwal M, et al. Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh, India. Clin Infect Dis. 2009;48:400–406.
   PubMed Web of Science ®Google Scholar
• Lee E, Pavy M, Young N, et al. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Antiviral Res. 2006;69:31–38.
   PubMed Web of Science ®Google Scholar
• Ishag HZ, Li C, Huang L, et al. Griffithsin inhibits Japanese encephalitis virus infection in vitro and in vivo. Arch Virol. 2013;158:349–358.
   PubMed Web of Science ®Google Scholar
• Ishag HZA, Li C, Wang F, et al. Griffithsin binds to the glycosylated proteins (E and prM) of Japanese encephalitis virus and inhibit its infection. Virus Res. 2016;215:50–54.
   PubMed Web of Science ®Google Scholar
• Haridas V, Rajgokul KS, Sadanandan S, et al. Bispidine-amino acid conjugates act as a novel scaffold for the design of antivirals that block Japanese encephalitis virus replication. PLoS Negl Trop Dis. 2013;7(1):e2005.
   PubMed Web of Science ®Google Scholar
• Ishag HZ, Li C, Huang L, et al. Inhibition of Japanese encephalitis virus infection in vitro and in vivo by pokeweed antiviral protein. Virus Res. 2013;171:89–96.
   PubMed Web of Science ®Google Scholar
• Shi Z, Wei J, Deng X, et al. Nitazoxanide inhibits the replication of Japanese encephalitis virus in cultured cells and in a mouse model. Virol J. 2014;11:10.
   PubMed Web of Science ®Google Scholar
• Fang J, Sun L, Peng G, et al. Identification of three antiviral inhibitors against Japanese encephalitis virus from library of pharmacologically active compounds 1280. PLoS One. 2013;8:e78425.
   PubMed Web of Science ®Google Scholar
• Wang S, Liu Y, Guo J, et al. Screening of FDA-approved drugs for inhibitors of Japanese encephalitis virus infection. J Virol. 2017;91:pii: e01055-17.
   Web of Science ®Google Scholar
• Marceau CD, Puschnik AS, Majzoub K, et al. Genetic dissection of Flaviviridae host factors through genome-scale CRISPR screens. Nature. 2016;535:159–163.
   PubMed Web of Science ®Google Scholar
• Zhang R, Miner JJ, Gorman MJ, et al. A CRISPR screen defines a signal peptide processing pathway required by flaviviruses. Nature. 2016;535:164–168.
   PubMed Web of Science ®Google Scholar
• Lopez-Sambrooks C, Shrimal S, Khodier C, et al. Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells. Nat Chem Biol. 2016;12:1023–1030.
   PubMed Web of Science ®Google Scholar
• Puschnik AS, Marceau CD, Ooi YS, et al. A small-molecule oligosaccharyltransferase inhibitor with pan-flaviviral activity. Cell Rep. 2017;21:3032–3039.
   PubMed Web of Science ®Google Scholar
• Touch S, Suraratdecha C, Samnang C, et al. A cost-effectiveness analysis of Japanese encephalitis vaccine in Cambodia. Vaccine. 2010;28:4593–4599.
   PubMed Web of Science ®Google Scholar
• Liu W, Clemens JD, Kari K, et al. Cost-effectiveness of Japanese encephalitis (JE) immunization in Bali, Indonesia. Vaccine. 2008;26:4456–4460.
   PubMed Web of Science ®Google Scholar
• Ding D, Kilgore PE, Clemens JD, et al. Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China. Bull World Health Organ. 2003;81:334–342.
   PubMed Web of Science ®Google Scholar
• Yin Z, Beeler Asay GR, et al. An economic evaluation of the use of Japanese encephalitis vaccine in the expanded program of immunization of Guizhou province, China. Vaccine. 2012;30:5569–5577.
   PubMed Web of Science ®Google Scholar
• Barzon L, Palù G. Current views on Zika virus vaccine development. Expert Opin Biol Ther. 2017;17:1185–1192.
   PubMed Web of Science ®Google Scholar
• Gaudinski MR, Houser KV, Morabito KM, et al. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet. 2017;pii: S0140-6736(17)33105–7.
   PubMed Web of Science ®Google Scholar
• Modjarrad K, Lin L, George S, et al. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet. 2017;pii: S0140-6736(17)33106–9.
   PubMed Web of Science ®Google Scholar
• Lobigs M, Larena M, Alsharifi M, et al. Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus. J Virol. 2009;83:2436–2445.
   PubMed Web of Science ®Google Scholar
• Lobigs M, Diamond MS. Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex. Expert Rev Vaccines. 2012;11:177–187.
   PubMed Web of Science ®Google Scholar
• Cao L, Fu SGao X, et al. Low protective efficacy of the current japanese encephalitis vaccine against the emerging genotype 5 japanese encephalitis virus. Plos Negl Trop Dis. 2016;10(5):e0004686.
   PubMed Web of Science ®Google Scholar
• Yamshchikov G, Borisevich V, Kwok CW, et al. The suitability of yellow fever and Japanese encephalitis vaccines for immunization against West Nile virus. Vaccine. 2005;23:4785–4792.
   PubMed Web of Science ®Google Scholar
• Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res. 2003;60:421–467.
   PubMed Web of Science ®Google Scholar
• The Lancet Infectious Diseases. The dengue vaccine dilemma. Lancet Infect Dis. 2018;18:123
   Google Scholar